首页> 外文期刊>Retina >Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy.
【24h】

Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy.

机译:曲安奈德辅助的pars平板玻璃体切除术治疗增生性玻璃体视网膜病变。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: To determine whether triamcinolone acetonide (TAAC) staining facilitates posterior hyaloid and epiretinal membrane (ERM) removal in patients undergoing pars plana vitrectomy (PPV) for rhegmatogenous retinal detachment (RRD) with proliferative vitreoretinopathy (PVR). METHODS: Ten consecutive pseudophakic patients (10 eyes) underwent PPV for RRD with PVR. After a core PPV, a few drops of a commercially available TAAC aqueous suspension (40 mg/mL) with vehicle were injected into the mid vitreous cavity to visualize the posterior hyaloid, thus allowing a complete posterior hyaloidectomy. Next, 0.1 to 0.2 mL of TAAC was applied on the retinal surface to visualize and peel the ERMs. The tamponading agent was silicone oil (1,300 cs) in eight eyes and perfluropropane (C3F8 14%) in two eyes. The minimal follow-up period in all patients was 4 months. RESULTS: In all patients, intraoperative staining with TAAC consistently improved direct visualization and delineation of the posterior hyaloid and ERMs and facilitated their removal. No adverse reaction related to the use of TAAC was observed immediately postoperatively or 4 months after surgery. CONCLUSIONS: Intravitreal TAAC may be an important adjuvant tool in the delineation of posterior hyaloid and ERMs, allowing for a more complete and safer ERM removal in the surgical management of PVR complicating RRD. It is well tolerated with all its vehicle if used at low concentration and rapidly removed during surgery.
机译:目的:确定曲安奈德(TAAC)染色是否可促进进行pars平板玻璃体切除术(PPV)和增生性玻璃体视网膜病变(PVR)的pars平板玻璃体切除术(PPV)患者的后透明膜和视网膜前膜(ERM)去除。方法:10例连续假晶状体患者(10眼)接受了PVR RRD和PVR。在进行核心PPV后,将几滴含有媒介物的TAAC水性悬浮液(40 mg / mL)注入玻璃体中腔,以可视化后玻璃体,从而完成后玻璃体切除术。接下来,将0.1到0.2 mL的TAAC应用于视网膜表面,以可视化和剥离ERM。棉球化剂在八只眼中是硅油(1300 cs),在两只眼中是全氟丙烷(C3F8 14%)。所有患者的最小随访期为4个月。结果:在所有患者中,术中TAAC染色均能持续改善后透明样玻璃体和ERM的直接可视化和轮廓,并有助于其去除。术后立即或术后4个月未观察到与使用TAAC相关的不良反应。结论:玻璃体腔内TAAC可能是确定后玻璃样骨和ERMs的重要辅助工具,可在PVR并发RRD的外科手术中更彻底,更安全地去除ERM。如果以低浓度使用并且在手术期间迅速去除,则其所有媒介物均具有良好的耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号